Company Overview
| Stock Name | 信達生物製藥 - B |
|---|---|
| Stock Code | 01801 |
| Company Full Name | 信達生物製藥 - B |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事研發抗體及蛋白質藥品、銷售自制品，以及提供有關技術轉讓、諮詢及服務。 |
| Listing Date | 2018-10-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區東平街168號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.innoventbio.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 13.98 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 58.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 330,417,300 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 16.58 |
|---|---|
| First Day Open | HK$ 14.3 |
| First Day Change | 18.60% |
| First Day Volume | 46747200.0 |
| First Day Turnover | 704900000.0 |
Use of Proceeds
| Use of Proceeds | 1、52%或約1640.8百萬港元用于撥資正在進行及計劃中的信迪利單抗(IBI-308)臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣） 2、8%或約252.4百萬港元用于撥資正在進行及計劃中的IBI-305臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）； 3、4%或約126.2百萬港元用于撥資正在進行及計劃中的IBI-301臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）； 4、1%或約31.6百萬港元用于撥資正在進行及計劃中的IBI-303臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）。 5、25%或約788.8百萬港元用于撥資正在進行及計劃中的其他管線候選藥物的臨床試驗、注冊備案的準備事宜及潛在的商業化推出（包括銷售及市場推廣）。 6、10%或約315.5百萬港元，用作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (4)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Far East) Limited CE AAB026
招商证券（香港）有限公司 CE AAI650
Overall Coordinators (5)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
招商证券（香港）有限公司 CE AAI650
华泰金融控股（香港）有限公司 CE AOK809
Joint Bookrunners (6)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
招商证券（香港）有限公司 CE AAI650
华泰金融控股（香港）有限公司 CE AOK809
香港上海汇丰银行有限公司
Joint Lead Managers (6)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
招商证券（香港）有限公司 CE AAI650
华泰金融控股（香港）有限公司 CE AOK809
香港上海汇丰银行有限公司
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 195,950,670 HKD | — | 5.90% | — | 6 months | 2019-04-30 |
| 2 | Elbrus Investments Pte. Ltd. | 156,995,400 HKD | — | 4.80% | — | 6 months | 2019-04-30 |
| 3 | LAV Biosciences Fund IV, L.P. | 156,757,740 HKD | — | 4.70% | — | 6 months | 2019-04-30 |
| 4 | Prime Capital Funds | 235,129,620 HKD | — | 7.10% | — | 6 months | 2019-04-30 |
| 5 | Rock Springs Capital Master Fund LP | 39,185,940 HKD | — | 1.20% | — | 6 months | 2019-04-30 |
| 6 | SCC Growth V Holdco L, Ltd. | 470,287,200 HKD | — | 14.20% | — | 6 months | 2019-04-30 |
| 7 | Seacliff (Cayman) Ltd. | 156,757,740 HKD | — | 4.80% | — | 6 months | 2019-04-30 |
| 8 | Vivo Funds | 117,571,800 HKD | — | 3.60% | — | 6 months | 2019-04-30 |
| 9 | 惠理基金管理香港有限公司 | 235,143,600 HKD | — | 7.10% | — | 6 months | 2019-04-30 |
| 10 | 景林资产管理有限公司 | 156,757,740 HKD | — | 4.70% | — | 6 months | 2019-04-30 |
Directors & Management
| Chairman | 俞德超 |
|---|---|
| Company Secretary | 王艷菊,陳濼而 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 淡馬錫控股(私人)有限公司(9.03%);俞德超(6.37%)；The Capital Group Companies, Inc.(5.96%) |
|---|
